{"id":241867,"date":"2026-07-30T17:23:15","date_gmt":"2026-07-30T22:23:15","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/07\/longterm-outcomes-in-idhwildtype-idhwt-gliomas-with-historical-who-grade-2-and-3-histology-neurooncology"},"modified":"2026-07-30T17:23:15","modified_gmt":"2026-07-30T22:23:15","slug":"longterm-outcomes-in-idhwildtype-idhwt-gliomas-with-historical-who-grade-2-and-3-histology-neurooncology","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/07\/longterm-outcomes-in-idhwildtype-idhwt-gliomas-with-historical-who-grade-2-and-3-histology-neurooncology","title":{"rendered":"Longterm outcomes in IDHwildtype (IDHwt) gliomas with historical WHO grade 2 and 3 histology NeuroOncology"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/longterm-outcomes-in-idhwildtype-idhwt-gliomas-with-historical-who-grade-2-and-3-histology-neurooncology.jpg\"><\/a><\/p>\n<p>A total of 134 patients were included, with a median follow-up of 29.8 months. Median OS was 35 months (95% CI: 28.8\u201343), and median PFS was 20.9 months (95% CI: 14.5\u201327.4). Grade 2 tumors demonstrated significantly improved outcomes compared to grade 3 tumors (median OS 94.5 vs. 29.8 months; median PFS 50.6 vs. 15.3 months). Among grade 3 tumors, sequential radiation and chemotherapy yielded a median OS of 29.8 months versus 29.8 months with concurrent chemoradiation followed by chemotherapy (<i>p<\/i> = 0.17); median PFS was 22.2 months versus.<\/p>\n<p>IDH-wt gliomas with grade 2\u20133 histology have heterogeneous outcomes. Grade 3 tumors show survival comparable to molecular glioblastoma, while a subset of grade 2 tumors exhibit prolonged survival. Concurrent chemoradiation did not confer a survival advantage over sequential therapy in grade 3 tumors, supporting reevaluation of treatment intensity in selected patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A total of 134 patients were included, with a median follow-up of 29.8 months. Median OS was 35 months (95% CI: 28.8\u201343), and median PFS was 20.9 months (95% CI: 14.5\u201327.4). Grade 2 tumors demonstrated significantly improved outcomes compared to grade 3 tumors (median OS 94.5 vs. 29.8 months; median PFS 50.6 vs. 15.3 months). [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-241867","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/241867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=241867"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/241867\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=241867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=241867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=241867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}